<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260818070716N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-02</date_registration>
      <primary_sponsor>Shiraz University</primary_sponsor>
      <public_title>The effects of red grape extract and beetroot extract on sports performance</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Simultaneous Red Grape and Beetroot Extract Supplementation Prior to Exercise-Induced Muscle Damage on Muscle Soreness, Strength, and Power Performance Metrics in female Volleyball Players</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-10-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>16</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/92965</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Basic scienece, Randomization description: Participants were allocated to the intervention and control groups using individual simple randomization based on a random number table. After eligible participants had been enrolled and assigned a unique identification code, the random number table was used for group allocation. The numbers in the table were read sequentially from a predefined starting point, and, according to a prespecified allocation rule, participants were assigned to either the intervention or control group, such that each participant was allocated to only one group. The allocation procedure was continued until the required sample size was reached. Group allocation was performed after eligibility had been confirmed, and the allocation result was recorded for each participant, Blinding description: Before the start of the test, based on a table prepared by a third party (other than the researcher), each subject was randomly assigned to one of the following conditions: 1-control (placebo), 2-placebo and grape extract, 3-placebo and red beet extract, and 4-grape extract and red beet extract. The researcher and the subjects were not informed of the contents of the table until the end of the test. The selection of supplement and placebo capsules was determined and noted by someone other than the researcher.</study_design>
      <phase>3</phase>
      <hc_freetext>Delayed onset muscle soreness, muscle damage, sports performance.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: beetroot extract. Intervention 2: Intervention group: red grape extract. Intervention 3: Intervention group: red grape and beetroot extract. Intervention 4: Control group: placebo.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Demographic characteristics and results related to main outcomes

When:
Access period starts from October 1405.

To whom:
Researchers working in scientific and academic institutions

Conditions:
No

Where to obtain:
Dr. Mohammed Hemmatinafar

How to obtain:
After approval by the supervisor, if the conditions are met, it will be sent within one month.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammed Hemmatinafar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eram Square, Eram Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194684334</zip>
        <telephone>+98 71 3613 3966</telephone>
        <email>m.hemmatinafar@shirazu.ac.ir</email>
        <affiliation>Shiraz University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammed Hemmatinafar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Eram Square, Eram Blvd</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7194684334</zip>
        <telephone>+98 71 3613 3966</telephone>
        <email>m.hemmatinafar@shirazu.ac.ir</email>
        <affiliation>Shiraz University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Girls aged 18-30-
People who have had continuous volleyball training for at least six months.
Completed an informed consent form to participate in the research</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Sports prohibition (complete the questionnaire (PAR-Q))
Allergy to beetroot and red grapes
Chronic diseases
Previous injury
Smoking and alcohol
Use of nutritional supplements, use of antibiotics and steroids or non-steroidal anti-inflammatory drugs one week before and during the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: beetroot extract</i_keyword>
      <i_keyword>Intervention group: red grape extract</i_keyword>
      <i_keyword>Intervention group: red grape and beetroot extract</i_keyword>
      <i_keyword>Control group: placebo</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Lower body flexibility. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: V-sit and reach test.</prim_outcome>
      <prim_outcome>Lower body explosive power. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: Sargent jump test.</prim_outcome>
      <prim_outcome>Upper body explosive power. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: Medicine ball throw from behind the head.</prim_outcome>
      <prim_outcome>Lower body isometric strength. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: Wall-sit test.</prim_outcome>
      <prim_outcome>Agility. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: T-agility test.</prim_outcome>
      <prim_outcome>Speed. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: 10- meters speed test.</prim_outcome>
      <prim_outcome>Abdominal muscle endurance. Timepoint: Before the intervention and 72 hours after the intervention and exercise-induced muscle soreness. Method of measurement: Sit-up test.</prim_outcome>
      <prim_outcome>Delayed onset muscle soreness. Timepoint: Before the intervention and 0, 12, 24, 48 and 72 hours after the exhausting session and the intervention. Method of measurement: Visual analogue scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>No. Timepoint: No. Method of measurement: No.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>No</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-04-21</approval_date>
        <contact_name>Ethics committee of Shiraz University</contact_name>
        <contact_address>Eram Blvd, Eram Square Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
